Interestingly, while the targeting of the PD1/PD-L1 axis in MM patients never demonstrated a significant clinical benefit [82,83,84], the possibility to combine these drugs with bispecifics or cell therapy is currently under study due to the overexpression of PD1 on exhausted (CAR-)T cells. This evidence concerns the gene PDCD1 and Miyoshi myopathy.